NEW YORK ( TheStreet) -- Shares of Biostar Pharmaceuticals (Nasdaq: BSPM) have taken a tremendous swing upward. The stock is trading at $2.05 as of 10:05 a.m. ET, 24.2% above Friday's closing price of $1.65. Volume is at 135,147, 1.9 times the daily average of 72,400. Biostar has a market cap of $17.4 million and is part of the health care sector and drugs industry. Shares are up 165.4% year to date as of the close of trading on Friday. Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products, and health supplement products for various diseases and conditions in the People's Republic of China. The company has a P/E ratio of 1.2, below the average drugs industry P/E ratio of 1.4 and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Biostar as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. You can view the full Biostar Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.
HOST // Robert Powell
Retirement Planning Event
More from Markets
Bears Think They've Finally Found This Market's Kryptonite
The question to ponder is whether the problem Friday is a longer-term issue or not.
Why Nike Stock Drops After Strong Earnings, Plus More
Plus, Tesla got downgraded, in what as divergence in opinions persist.
Dow Slammed on Weak Global Manufacturing Data; Inverted Yield Curve Hits Banks
Stocks closed sharply lower Friday after Wall Street was rattled by weaker-than-expected manufacturing data in the U.S. and Europe.
Nike Stock Slides to Second Biggest One-Day Drop in Two Years
Nike gave up nearly two months of gains after an earnings release accelerated selling action.